Open

Reduced Treatment after Surgery in Triple Negative Breast Cancer Patients

In this study, we want to learn if observation after surgery will be as effective at preventing cancer from coming back as completing 6 more months of pembrolizumab after surgery.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

At each visit you will have a blood draw and physical exam. If you are on the treatment arm, you will receive a 30 minute infusion every 3 weeks. The study also asks you to complete surveys at different intervals. We will follow-up with you every 6 months for 5 years.

In-person visits:
13-21

Total length of participation:
6 years

Looking for Specific Volunteers

Able to participate:

You have triple negative breast cancer

Not eligible if:

Your cancer is stage IV (metastatic)
You have cardiac disease
You are taking immunosuppressive medications
You have had prior breast cancers

Contact the Team

Visit Location

Contact & Visit Location

Additional Study Information

Principal Investigator

Sriraksha Jayananda
UNC Hospitals - Rex

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Breast)

IRB Number

23-1595

ClinicalTrials.gov

NCT05812807

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.